GlassScriptPhysician profile
Tobie R Morrow
NPI 1720196868
$1,575.41
in general payments reported to CMS, 2019-2025
27 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.24 · 2020: $25.31 · 2021: $696 · 2022: $513 · 2023: $70.25 · 2024: $51.11 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $323.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $322.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $199.67 | 2021 | |
| Medtronic, INC. | $171.04 | 2022-2025 | Intellis Adaptivestim, Symplicity G3 |
| Biohaven Pharmaceutical Holding Company LTD. | $129.48 | 2022 | |
| Novo Nordisk INC | $123.56 | 2020-2024 | Ozempic, Rybelsus |
| Amgen INC. | $115.88 | 2019-2022 | |
| Abbvie INC. | $113.18 | 2021-2023 | |
| Eisai INC. | $94.37 | 2021-2022 | |
| Amarin Pharma, INC. | $74.24 | 2020-2022 | |
| Daiichi Sankyo INC. | $63.95 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $61.43 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $60.96 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.11 | 2022 | |
| Pfizer INC. | $41.05 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.92 | 2021 | |
| Nevro Corp. | $33.66 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $29.74 | 2021-2023 | Arexvy |
| Sumitomo Pharma America, INC. | $28.95 | 2025 | Gemtesa |
| Cranial Technologies, INC | $20.83 | 2025 | Doc Band |
| Grifols USA, LLC | $20.00 | 2024 | Prolastin-C Liquid |
| Abbott Laboratories | $14.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.05 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.04 | 2022 | |
| Astellas Pharma US INC | $12.53 | 2021 | |
| Merck Sharp & Dohme LLC | $12.31 | 2021 | |
| Esperion Therapeutics, INC. | $12.16 | 2021 | |
| Sunovion Pharmaceuticals INC. | $11.96 | 2021 | |
| Lilly USA, LLC | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tobie Morrow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.